Quick Answer
Cue Biopharma, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $27.47 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +195.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Cue Biopharma, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 2,303.8%.
- Historical annual values: Fiscal year 2025: $27.47 million | Fiscal year 2024: $9.29 million | Fiscal year 2023: $5.49 million | Fiscal year 2022: $1.25 million | Fiscal year 2021: $14.94 million | Fiscal year 2020: $3.15 million | Fiscal year 2019: $3.46 million | Fiscal year 2018: $1.14 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: